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Hemochromatosis type 2 gene (HFE2) is 
highly expressed in skeletal muscle and liver 
hepatocytes.  Its encoded protein, hemojuvelin 
(HJV), is a co-receptor for the bone 
morphogenetic proteins 2 and 4 (BMP2 and 
BMP4) and enhances the BMP-induced 
hepcidin expression.  Hepcidin is a central iron 
regulatory hormone predominantly secreted 
from hepatocytes.  HJV also binds neogenin, a 
membrane protein widely expressed in many 
tissues.  Neogenin is required for the processing 
and release of HJV from cells.  The role that 
neogenin plays in HJV trafficking was 
investigated, using HepG2 cells, a human 
hepatoma cell line.  Knockdown of endogenous 
neogenin markedly suppresses HJV release, but 
has no evident effect on HJV trafficking to the 
plasma membrane.  Addition of a soluble 
neogenin ectodomain to cells markedly inhibits 
HJV release, indicating that the HJV shedding 
is not processed before trafficking to the cell 
surface.  At the plasma membrane it undergoes 
endocytosis in a dynamin-independent but 
cholesterol-dependent manner. The additional 
findings that HJV release is coupled to 
lysosomal degradation of neogenin, that HJV 
undergoes endocytosis, and that cholesterol 
depletion by filipin blocks both HJV 
endocytosis and HJV release, suggest that 
neogenin-mediated HJV release occurs after 
the HJV-neogenin complex is internalized from 
the cell surface.  
 
Iron is an essential nutrient for a variety of 
biochemical processes.  Iron uptake into the body 
via the intestines is controlled primarily by 
hepcidin (1).   Hepcidin, a central iron-regulatory 
peptide hormone, is predominantly produced by 
hepatocytes, circulates in blood and is excreted in 
urine (1-5).  Hepatic hepcidin expression is 
regulated by dietary or parenteral iron loading, 
iron stores, erythropoietic activity, tissue hypoxia 
and inflammation (1).   Hepcidin deficiency 
resulting from the primary mutations in human 
hemochromatosis gene (HFE1), transferrin 
receptor 2 gene (TFR2), hemochromatosis type 2 
gene (HFE2), or the hepcidin gene itself (HAMP), 
is the major cause of hereditary hemochromatosis 
(HH) (6).  This heterogeneous group of inherited 
iron overload disorders has a wide range of 
clinical severity.  
HFE2 is a recently cloned gene in humans and 
encodes a protein termed hemojuvelin (HJV)(7).  
Its ortholog in mice is called repulsive guidance 
molecule c (RGMc) because it is the third member 
of RGM family to be cloned (7-10).  RGMa and 
RGMb are expressed primarily in the developing   
and adult central nervous system, which do not 
overlap with HFE2 expression (8-10).   
The importance of HJV in iron homeostasis has 
been demonstrated by the observations that the 
homozygous or compound heterozygous mutations 
of HFE2 gene cause the type 2A juvenile 
hemochromatosis (JH), a particularly severe form 
of HH (7,11,12).  Disruption of both HFE2 alleles 
(Hjv-/-) in mice also causes a severe iron overload 
(5).  The marked suppression of hepatic hepcidin 
expression detected in JH patients with the HFE2 
mutation as well as in the Hjv-/- mice has 
implicated HJV as a key upstream regulator of 
hepatic hepcidin expression (5,7,13). In the liver, a 
recent study using lacZ as a marker indirectly 
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showed a selective expression of HJV in periportal 
hepatocytes (5).  The hepatocyte is, therefore, the 
principal site in which HJV exerts its regulatory 
role on hepcidin expression.   
Like the other two RGM family members 
(RGMa and RGMb), HJV is a co-receptor for the 
bone morphogenetic proteins 2 and 4 (BMP2 and 
BMP4).  HJV enhances hepatic hepcidin 
expression via the BMP signaling pathway (14).  
Neither RGMa nor RGMb appears to play a role in 
the regulation of hepcidin expression.  BMPs are 
cytokines of TGFβ superfamily that exhibit 
multiple roles in a wide variety of processes 
through different signaling pathways (15,16).  
BMP signaling is initiated upon ligand binding to 
BMP receptors, which leads to a sequential 
phosphorylation of receptor-activated Smads 
(Smad1, Smad5, and Smad8).  The phosphorylated 
Smad1/5/8 form heteromeric complexes with 
Smad4.  Upon formation, the complex translocates 
from the cytoplasm to the nucleus to regulate gene 
expression (17).  Recent findings showing that 
liver-specific disruption of Smad4 markedly 
decreases hepcidin expression and causes iron 
accumulation in mice (18), also support the 
importance of BMP signaling in iron homeostasis. 
The regulation of HJV appears to be primarily 
at the post-transcriptional level. HFE2 is expressed 
highly in both skeletal and heart muscle, and at 
lower levels in liver (7).  HFE2 mRNA levels do 
not vary with iron loading in the liver of mice or 
with iron depletion in the skeletal muscle of rats 
(19,20). The levels of serum HJV do increase in 
the early phase of iron deficiency in rats (20).  
HJV is a GPI-anchored protein (21) and in vitro 
studies demonstrated that HJV undergoes active 
release (shedding) from the HFE2-transfected cells 
as well as from the differentiated C2 or C2C12 
cells (mouse myoblast cell lines), which robustly 
express endogenous HJV (20,22,23).  In 
agreement with the finding in iron-deficient rats, 
HJV release from the cell lines is inhibited by 
iron-saturated Tf (holo-Tf) or non-Tf iron salts 
(20,22,24,25).  The observations that no evident 
defect in muscle development is observed in JH 
patients and Hjv-/- mice, rule out the possibility 
that HJV has a primary role in muscle 
development (7,11,12).  However, skeletal muscle, 
accounting for about 35 – 40% of body weight, 
has the highest expression of HFE2 mRNA (7), 
and is also a significant iron consumer for 
myoglobin synthesis with serum Tf presumably as 
its source of iron.  The findings that soluble HJV 
plays a critical role in the negative regulation of 
hepatic hepcidin expression through BMP 
signaling in hepatocytes, support the idea that 
skeletal muscle may serve as a body iron sensor as 
well as the major source of serum HJV to 
indirectly modulate hepatic hepcidin expression by 
regulating the HJV release into the circulation 
(20,22,26,27). 
HJV also binds neogenin, a receptor for RGMa 
and netrins (28,29).  Neogenin is a membrane 
protein and widely expressed in most tissues, 
including liver and skeletal muscle (30-34).  The 
interactions of neogenin with RGMa and netrins 
are essential for neural development (35,36).  Our 
previous study showed that the interaction with 
neogenin is required for HJV release from muscle 
cells (20).  The G320V mutation in HJV accounts 
for about two-thirds of cases of type 2A JH.  This 
mutation disrupts the interaction of HJV with 
neogenin, blocks HJV release, and results in the 
decreased HJV targeting to the cell surface and the 
retention of HJV in the endoplasmic reticulum 
(ER) (7,20,21,37).  These findings imply that 
neogenin may play a critical role in HJV 
intracellular trafficking.  How neogenin is 
involved in this process remains to be elucidated. 
In this study, we investigated the role of 
neogenin in HJV trafficking in HepG2 cells. We 
found that knockdown of endogenous neogenin 
markedly suppresses HJV release, but has no 
evident effect on HJV trafficking to the plasma 
membrane.  Release of HJV requires not only 
neogenin but also endocytosis presumably by a 
cholesteral-sensitive and dynamin-independent 
pathway.  
 
EXPERIMENTAL PROCEDURES 
 
Cell culture and transfection. HepG2 cells were 
purchased from ATCC, and maintained in 
MEM/10% FCS/1 mM pyruvate/1x non-essential 
amino acids (complete medium).  HepG2 cells 
stably expressing G320V (G320V-HepG2) were 
generated using Nucleofector kit V (Amaxa 
Biosystems) as previously described (20). The 
G320V mutant HFE2 cDNA was prepared as 
previously reported (21).  HepG2 cells stably 
transfected with wild type HFE2 (HJV-HepG2) or 
pcDNA3 empty vector (control-HepG2) were 
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generated previously (20).  The stably transfected 
cells were maintained in complete medium with 
800 µg/ml G418.   
Knockdown of endogenous neogenin.   
Neogenin siRNA (Dharmacon) was used to knock 
down the endogenous neogenin in control and 
HJV-HepG2 cells as previously described (20).  
RNAiMAX reagent (Invitrogen) was used for the 
transfection.  The negative control siRNA was the 
same as previously described (20). Cells were 
transfected with the siRNA twice on day 1 and day 
3 to maximize the efficacy of the knockdown.  
HJV in cell lysates and the conditioned medium 
(CM) and neogenin in cell lysates were analyzed 
by western blot. 
Flow cytometry analysis.  Flow cytometry 
analysis was used to quantify the cell surface HJV 
in HJV-HepG2 cells with or without neogenin 
knockdown.  Briefly, cells were first detached 
from flasks with the cell dissociation buffer 
(Invitrogen).  Cells were then incubated with 
affinity-purified rabbit anti-HJV antibody (4 
µg/ml) in Hanks Buffer supplemented with 3% 
fetal bovine serum for 30 min at 4°C, followed by 
incubation with phycoerythrin-conjugated goat 
anti-rabbit IgG (1:500 dilution; Caltag, 
Burlingame, CA) in the same buffer for 30 min at 
4°C.  Flow cytometry analysis was performed on a 
Becton Dickinson FACSCalibur flow cytometer at 
the Core Facility of OHSU.  Rabbit IgG and 
control-HepG2 cells were used as negative 
controls.  The levels of cell surface HJV are 
expressed as arbitrary units.  We used the standard 
deviation (SD) and the paired and two-tailed 
Student’s T-Test to evaluate the statistical 
significance of the cell surface HJV in HepG2 
cells with or without neogenin knockdown. 
Phosphatidylinositol-specific phospholipase C 
(PI-PLC) cleavage of cell surface HJV.  
Approximately 106 HJV-HepG2 cells in 6-well 
plate were incubated in 0.5 ml of plain MEM 
medium in presence or absence of PI-PLC 
(Molecular Probes) at the concentration of 1 
unit/ml at 37°C in 5% CO2 incubator or at 4°C for 
the time intervals indicated in the text.  
Supernatants were collected, and cell lysates were 
prepared using NET-Triton buffer (150 mM NaCl, 
5 mM EDTA, and 10 mM Tris (pH 7.4) with 1% 
Triton X-100) with 1x protease inhibitors cocktail 
(Roche).  Approximately one third of the cell 
lysates or supernatants was subjected to 11% SDS-
PAGE, followed by immunodetection of HJV and 
neogenin as described in the Immunodetection 
section.  
HJV release.  The effects of the ectodomain 
(extracellular domain) of neogenin, bafilomycin A 
(an inhibitor of the vacuolar H+-ATPase, Sigma), 
dynasore (a cell-permeable inhibitor of dynamin, 
Sigma), and filipin (a cholesterol-binding agent, 
Sigma) on HJV release from HJV-HepG2 cells 
were examined.  The ectodomain of neogenin was 
generated by sub-cloning the neogenin cDNA 
encoding the hydrophobic signal sequence 
(residues 1 – 33) and the ectodomain (residues 34 
to 1103) with a C-terminal 6x-His tag into the 
pVL1393 baculovirus transfer vector (BD 
Biosciences).  The recombinant protein was 
purified from the supernatant of baculovirus-
infected High 5 cells using Ni-NTA and gel 
filtration chromatography. HJV-HepG2 cells were 
cultured in the 12-well plates.  After 48 hr of 
incubation with 60% confluence, fresh MEM/5% 
FCS was changed with the addition of neogenin 
ectodomain at 0, 250, 500, 750, and 1,000 nM, and 
incubated for 24 hr.  HJV in about 50% of cell 
lysate and 20% of the conditioned culture medium 
(CM) was analyzed by western blot.  For the 
inhibitors, experiments were conducted when 
HJV-HepG2 cells were ~80% confluence.  Cells 
were incubated in the absence or presence of 
bafilomycin A (100 nM), dynasore (80 and 160 
µM), or filipin (1, 5 and 10 µg/ml) for the 
indicated time intervals where no evident 
cytotoxicity was detected.  The whole cell lysate 
and 50% of CM were analyzed.   
Expression of wild type and mutant dynamin.  
In order to block dynamin-mediated endocytosis 
adenoviruses were used to infect cells to introduce 
wild type or K44A mutant dynamin-1 (dynamin) 
into HJV-HepG2 cells.  The viruses were kindly 
provided by Dr. Sandra Schmid at The Scripps 
Research Institute, La Jolla, CA.  The viral 
infections were conducted as described previously 
with some modifications (38).  Briefly, HJV-
HepG2 cells were sub-cultured into 12-well plates 
about 24 hrs before the infection.  Cells were 
overlaid with 250 µl of binding medium (Hank’s 
salts containing 1 mM MgCl2, 1 mM CaCl2, and 
10 mM Hepes, pH7.2) containing the mixture of 
tTA-activator virus and wild type or K44A-
dynamin-1 virus at equal ratio.  To generate the 
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cells with various levels of dynamin, different 
amounts of virus were added as indicated in the 
text.  After 2 hr incubation at 37°C to enable viral 
attachment and infection, binding medium was 
changed to complete medium.  After 18 hr 
incubation to allow the expression of introduced 
dynamin, the medium was replaced with 600 µl of 
fresh complete medium.  The cultured conditioned 
medium was collected to assay HJV release after 
additional 24 hr incubation.  The levels of 
dynamin in cell lysate were analyzed as described 
in the Immunodetection section.  In this study, 
cells infected with tTA-activator virus alone were 
served as negative controls.    
HJV internalization.  The internalization of 
biotinylated cell surface-HJV was conducted as 
previously described (39-41).  Briefly, HJV or 
control-HepG2 cells in 6-well plate at ~80% 
confluence were biotinylated with 0.25 mg/ml 
Sulfo-NHS-Biotin (Pierce) at 4°C for 20 min.  
Cells were then incubated at 37°C for the time 
intervals indicated in the text.  Biotin remaining on 
cell surface was stripped using sodium 2-
mercaptoethanesulfonate (MesNa, Sigma) at 4°C.  
Alternatively, cells were incubated in presence of 
PI-PLC (1 unit/ml) at 4°C for 3 hr to release the 
cell surface GPI-anchored proteins.  Cells were 
then solubilized in NET-Triton/1x protease 
inhibitors cocktail, followed by using streptavidin 
agarose beads (Pierce) to isolate the biotinylated-
HJV (internalized fraction).  The total cell surface 
HJV was isolated with strepavidin agarose from 
biotinylated cells labeled at 4˚C.  
125I-Tf uptake.  125I-Tf uptake was used to detect 
the effect of dynasore and filipin on TfR1-
mediated Tf uptake.  The rate of 125I-Tf uptake was 
determined as described previously (42) with the 
following modifications.  HepG2 cells in 6-well 
plates were first pre-incubated in 1 ml of uptake 
medium (MEM, 2 mg/ml ovalbumin, 20 mM 
Hepes, pH 7.2) with dynasore (80 and 160 µM) or 
filipin (10 µg/ml) for 30 min at 37°C.  125Tf uptake 
was then initiated by changing to the uptake 
medium containing 50 nM 125Tf as well as the 
same concentrations of dynasore or filipin.  The 
inclusion of 1 mg/ml unlabeled Tf was used as the 
control for non-specific uptake.  After an 8 min 
incubation at 37°C, externally bound Tf was 
stripped by acid wash.  The radioactivity 
remaining within cells was counted.  The amount 
of specific uptake in the presence of inhibitors was 
expressed as the percentage of corresponding 
controls.  Standard deviation (SD) and the paired 
and two-tailed Student’s T-Test were used to 
evaluate the statistical significance between the 
groups with and without inhibitors. 
Immunodetection.  Cell lysate protein and 
conditioned culture medium (CM) were subjected 
to SDS-PAGE under reducing conditions, 
followed by transfer onto nitrocellulose 
membrane.  Membranes were probed with 
affinity-purified rabbit anti-HJV antibody (0.22 
µg/ml), rabbit anti-neogenin antibody (0.4 µg/ml, 
Santa Cruz Biotechnology), mouse anti-dynamin 
(1:4000, Upstate) or mouse anti-β-actin antibody 
(1:10,000, Chemicon International), followed by 
immunodetection using corresponding horseradish 
peroxidase (HRP)-conjugated secondary antibody 
(Chemicon International, Temecula, CA).  Bands 
were exposed to X-ray film by chemiluminescence 
(Super Signal, Pierce, Rockville).  
 
RESULTS 
 
Knockdown of endogenous neogenin has no 
effect on HJV trafficking to the plasma membrane, 
but blocks HJV release.  Our previous studies 
demonstrate that HJV interacts with neogenin in 
HEK293 cells and that interaction with neogenin 
is required for HJV release in C2C12 cells, a 
mouse myoblast cell line (20,21).  Recent studies 
indicate that the G320V mutant form of HJV that 
does not bind neogenin remains predominantly in 
the ER and does not traffic efficiently to the 
plasma membrane (21,37).  These observations 
suggest a critical role of neogenin in HJV 
trafficking.  To gain insight into the function of 
neogenin in this process, we first examined its role 
in HJV trafficking to the plasma membrane in 
HepG2 cells.  HepG2 cells are a relatively well-
differentiated human hepatoma cell line that 
expresses many hepatocyte-specific genes 
including Tf, hepcidin, TfR2 and ceruloplasmin 
(data not shown).  The endogenously expressed 
neogenin is readily detectable by western blot 
(Fig. 1A).  We used siRNA to knock down the 
neogenin in HepG2 cells stably transfected with 
HJV (HJV-HepG2), and then quantified the levels 
of cell surface HJV by flow cytometry analysis.  In 
comparison with the control siRNA, siRNA 
specific to human neogenin was able to eliminate 
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detectable neogenin (Fig. 1A).  Flow cytometry 
analysis revealed a mild but not statistically 
significant increase (p=0.36) (Fig. 1C).  Similar 
results were obtained by immunofluorescent 
analysis of non-permeabilized cells (data not 
shown).  To confirm the lack of change in cell 
surface HJV with the knockdown of neogenin, we 
examined the amount of HJV released by PI-PLC, 
which cleaves the phosphodiester bond of GPI-
linked proteins. Similar quantities of HJV were 
released upon PI-PLC cleavage whether or not 
neogenin was present in the cells (Fig. 1A).  
Consistent with the previous reports showing 
complex processing of HJV (21,23), three distinct 
HJV bands migrating at approximate 50, 33 and 
15 kD were detected in the supernatants of PI-PLC 
digestion (Fig. 1A, lower panel).  Down regulation 
of neogenin does not alter this profile.  Taken 
together, these results indicate that neogenin is not 
required for HJV trafficking to the plasma 
membrane. 
Since neogenin did not affect the biosynthetic 
pathway of HJV, the effect of neogenin on the 
shedding of HJV was examined.  Detection of 
HJV in the conditioned medium (CM) by western 
blot analysis revealed a marked decrease of 
released HJV when neogenin was depleted (Fig. 
1B).  The multiple HJV bands migrating at about 
37 kD in the conditioned medium are in agreement 
with the previous observations (20,23), implying 
the existence of multiple cleavage sites (Fig. 1B).   
These results suggest that both myocytes and 
hepatocytes share similar pathways of neogenin-
mediated HJV release.  Importantly, these results 
also imply that neogenin influences the shedding 
of HJV after it traffics to the cell surface.  
Soluble neogenin inhibits HJV release.  
Neogenin is a type I transmembrane protein 
consisting of an extracellular ectodomain, a 
transmembrane domain and a cytoplasmic domain 
(33).  The binding of neogenin to HJV has been 
mapped to the ectodomain of neogenin with a 
binding affinity of approximately 500 nM (43).  
We used purified ectodomain of neogenin to 
competitively disrupt the HJV-neogenin 
interaction at the cell surface and then examined 
the effect of this disruption on HJV release.  In 
this study, we directly added ectodomain of 
neogenin to the culture medium of HJV-HepG2 
cells.  After 24 hr of incubation, HJV in the 
cultured conditioned medium was analyzed by 
western blot.  In comparison with the parallel 
controls showing active HJV release, the dose-
response to neogenin ectodomain indicates that 
inhibition of HJV release was achieved over a 
similar concentration range as the binding affinity 
(Fig. 2, top panel).  A similar inhibition of HJV 
release was observed when neogenin expression 
was knocked down using neogenin siRNA (Fig. 
1B).  Endogenous neogenin levels increase 
slightly upon treatment with the ectodomain 
fragment (Fig. 2; lower panel), indicating that the 
binding of soluble neogenin to HJV could inhibit 
the downregulation of endogenous neogenin by 
HJV.  Together with the neogenin knockdown 
studies, these results indicate that the neogenin 
fragment competes with the endogenous neogenin 
for binding to HJV.  The interaction of HJV with 
full-length neogenin is essential for both the 
processing and release of HJV as well as for the 
downregulation of neogenin after HJV reaches the 
cell surface.  
HJV release is correlated with neogenin 
degradation.  We observed that expression of HJV 
in HepG2 cells resulted in lower levels of 
endogenous neogenin (20).  To further evaluate 
the role of HJV in the downregulation of 
neogenin, we first compared the effect of wild 
type and G320V HJV expression on the level of 
neogenin.  The G320V mutant, which does not 
bind neogenin, was used as a negative control. 
Wild type HJV but not the G320V mutant, 
markedly decreased neogenin protein levels and 
undergoes active release (Fig. 3A).  A similar 
effect obtained in at least three individual stably 
transfected clones for each construct ruled out a 
clonal effect (data not shown).  Alternatively, we 
used PI-PLC, which can release cell surface HJV 
into the medium, to determine the effect of HJV 
on neogenin levels.  PI-PLC was directly added 
into the culture medium of HepG2 cells expressing 
HJV or G320V HJV at 37°C, and cells were 
incubated for 3 hr.  Under these conditions, PI-
PLC is expected to release HJV.  If the full-length 
HJV-neogenin complex is required for 
internalization and neogenin degradation, 
treatment of HJV-HepG2 cells with PI-PLC 
should release HJV from cell and elevate the 
cellular neogenin level.  Consistent with this 
hypothesis, PI-PLC released HJV, and resulted in 
a marked increase of neogenin after 3-hr 
incubation, as compared to the corresponding 
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controls with no PI-PLC (Fig. 3B).  Importantly, 
an increase of neogenin was not detected in the 
empty vector-transfected control or in G320V 
HepG2 cells where the G320 HJV mutant is 
located mainly in the ER (Fig. 3B) or in HJV-
HepG2 cells at 4°C (data not shown).  These 
results suggest that HJV and neogenin internalize 
prior to neogenin degradation.   
The increased neogenin degradation could 
result from the following two possibilities, the 
release of HJV/neogenin as a complex /or the 
sorting to and degradation of neogenin in 
lysosomes.  No shed neogenin could be detected in 
the concentrated conditioned medium from HJV-
HepG2 cells by western blot analysis under 
conditions where cellular neogenin decreased 
(data not shown).    To determine if neogenin is 
degraded in lysosomes, we treated HJV-HepG2 
cells with bafilomycin A, an inhibitor of the 
vacuolar H+-ATPase (44), which dissipates the pH 
gradient in the intracellular organelles and thereby 
blocks protein degradation in lysosomes.  After a 4 
hr incubation with 100 nM bafilomycin A, a 
significant increase of cellular neogenin in HJV-
HepG2 cells was apparent (Fig. 3C).  Interestingly, 
HJV release does not seem to be altered.  These 
results suggest that lysosome is the site of 
neogenin degradation and that HJV shedding does 
not depend on low pH.  In addition, the mild 
increase of cellular HJV in presence of 
bafilomycin A (Fig. 3C) also implies that HJV 
release might not be the sole pathway for cellular 
HJV turnover. Rather, a certain portion of HJV 
may also be degraded in lysosomes.  Taken 
together, the above observations imply that the 
interaction of neogenin with HJV triggers its 
internalization from plasma membrane for either 
cleavage or lysosomal degradation. 
HJV release is inhibited by cholesterol 
depletion, but not by dynamin inhibitors.  Plasma 
membrane proteins can be internalized by at least 
four known pathways, three of which require 
dynamin for fission of the invaginated vesicles 
from the plasma membrane (45).  To determine if 
HJV release from cells was dependent on its 
endocytosis, we examined whether the disruption 
of dynamin function affects HJV release from 
HJV-HepG2 cells.  Initially, dynasore, a cell-
permeable inhibitor specific for the dynamin 
GTPase (46), was used to inhibit endocytosis.  
Unexpectedly, no evident effect was detected 
when cells were incubated in the presence of 
dynasore at the recommended concentrations (80 
and 160 µM) (Fig. 4A).  To test whether these 
cells were sensitive to dynasore, the effect of 
dynasore on 125I-Tf uptake was measured since 
TfR-mediated Tf uptake is a dynamin-dependent 
process.  Consistent with the previous 
observations (46),  dynasore significantly inhibited 
and completely blocks 125Tf internalization at 80 
and 160 µM, respectively (Fig. 4B).  These results 
suggest that HJV release is independent of 
dynamin.  
To further substantiate this observation, we 
next examined the effects of the K44A mutant 
dynamin.  The K44A mutation disrupts the 
dynamin GTPase activity.  It is widely used as a 
dominant-negative to block the dynamin-
dependent endocytosis (38).  HJV-HepG2 cells 
were infected with four different concentrations of 
adenovirus encoding either wild type or K44A 
mutant dynamin.  Consistent with the dynasore 
results, no evident inhibition of HJV release was 
detected when cells were infected with the virus 
encoding the K44A dynamin mutant (Fig. 4C).  
These results again support that dynamin-
dependent endocytosis is not involved in HJV 
release.  
HJV is a GPI-anchored protein (21).  Depletion 
of cholesterol by filipin, a sterol-binding agent that 
binds to cholesterol, disrupts both the endocytosis 
and exocytosis of GPI-anchored proteins (45,47-
49).  Therefore, we examined the effect of filipin 
on HJV release from HJV-HepG2 cells.  Filipin 
was added directly to the culture medium at the 
concentrations ranging from 0 to 10 µg/ml.  Cells 
were incubated for 2 hr at 37°C.  A marked 
decrease of HJV in the conditioned medium was 
evident in the presence of 10 µg/ml of filipin (Fig. 
4D).  Longer periods of incubation were not 
pursued because of the cytotoxicity of filipin.  
Alternatively, the effects of filipin on the release 
of biotinylated HJV were measured.  Consistent 
with the above finding, filipin was also found to 
markedly suppress the release of HJV, which was 
derived from the cell surface (Fig. 4E). Further 
analysis revealed that filipin does not significantly 
alter the 125Tf internalization compared to the 
control (P=0.4997)(Fig. 4B).  The relatively large 
variability in Tf uptake may result from the effect 
of cholesterol depletion on clathrin-coated pit 
internalization.  Previous studies showed that the 
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acute cholesterol depletion markedly reduces the 
rate of internalization of TfR1 by more than 85% 
(50).  These results suggest that HJV release 
depends on cholesterol and possibly on 
cholesterol-dependent HJV endocytosis.   
Endocytosis of hemojuvelin. To elucidate 
whether cell surface HJV undergoes endocytosis, 
cell surface proteins were labeled at 4°C with a 
cleavable form of biotin.    Less than 10% of the 
total HJV was biotinylated, suggesting that the 
majority of HJV is localized intracellularly (Fig. 
5A).  To detect internalized HJV, cells were 
warmed to 37˚ C for 10 min.  Any biotin 
remaining on cell surface was stripped by the non-
permeable reducing agent, MesNa. The 
internalized HJV was then isolated using 
streptavidin agarose beads.   Controls showed that 
MesNa could strip most of the biotin coupled to 
HJV in HJV-HepG2 cells left at 4°C (Fig. 5A).  
Internalization was a rapid process.  The 
internalized HJV was detectable by western blot 
after 5 min of incubation and reaches plateau after 
10 min of incubation (Fig. 5A and data not 
shown).  Similar results were also obtained by 
using PI-PLC to strip the cell surface HJV (data 
not shown).  These findings indicate that HJV 
undergoes endocytosis in HepG2 cells.  
HJV endocytosis is via dynamin-independent 
but possibly cholesterol-dependent pathway.   To 
further characterize the pathway of HJV 
endocytosis, we examined the effect of filipin and 
dynasore on the internalization of biotinylated cell 
surface HJV in HJV-HepG2 cells.  HJV 
internalization was markedly inhibited when cells 
were incubated in the presence of 10 µg/ml filipin 
(Fig. 5B). However, no evident inhibition was 
detected when cells were incubated in the presence 
of dynasore at the concentrations of 80 and160 
µM (Fig. 5B; data not shown).  These results 
suggest that HJV endocytosis is via the dynamin-
independent and cholesterol-dependent pathway, 
although the definitive role of cholesterol in this 
process still remains to be further characterized by 
other strategies.   
 
DISCUSSION 
 
The role of neogenin in HJV trafficking in 
HepG2 cells was investigated.  Our results show 
that knockdown of endogenous neogenin 
markedly suppresses HJV release, but has no 
evident effect on HJV trafficking to the plasma 
membrane.  The marked inhibition of HJV release 
by soluble neogenin suggests that the neogenin-
regulated HJV release occurs after HJV traffics to 
the plasma membrane.  Furthermore, our data also 
indicate that HJV shedding occurs after HJV is 
internalized.  
HJV is a GPI-anchored protein (21) and, like 
other GPI-linked proteins, is co-translationally 
translocated  into the ER where they are linked to 
a GPI anchor before trafficking to the cell surface 
(51).  In this study, we excluded the possibility 
that HJV release occurs in its biosynthetic 
pathway.  The observation that neogenin 
knockdown does not alter the HJV trafficking to 
the cell surface, but does block the HJV release 
supports this assumption.  In addition, these 
findings also have an important implication with 
respect to the possible defects of G320V mutation 
in HJV.  The G320V mutation is the most 
frequently detected mutation in type 2A juvenile 
hemochromatosis, accounting for about two-thirds 
of cases (7).  G320V mutation abolishes the HJV-
induced hepcidin expression (14). Early studies 
demonstrated that it disrupts the interaction of 
HJV with neogenin, and that G320V mutant HJV 
has a decreased targeting onto cell surface, is 
slightly shed, and is largely retained in the ER 
(7,20,21,23,37)(unpublished observations).  Since 
neogenin is not required for HJV trafficking to the 
plasma membrane, the primary defect of the 
G320V mutation appears to be misfolding, which 
consequently blocks its exit from the ER, the 
subsequent trafficking to the plasma membrane, as 
well as lack of the interaction with neogenin.  
HJV release takes place after it traffics to the 
plasma membrane and binds neogenin.  The 
finding that HJV can efficiently traffic to the 
plasma membrane in absence of neogenin but does 
not undergo release, rules out the possibility that 
neogenin acts as a chaperone to traffic HJV to the 
cell surface.  Rather, the association with neogenin 
is a prerequisite for shedding, since soluble 
neogenin ectodomain can competitively inhibit 
HJV release, similar to neogenin knockdown.  The 
finding that addition of soluble neogenin 
ectodomain does not result in the depletion of 
endogenously expressed neogenin in cells but 
rather a slight increase in endogenous neogenin, 
suggests that the inhibition of HJV release is 
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8 
caused by competitively disrupting the interaction 
of HJV with endogenous neogenin. These 
observations, therefore, implicate a critical role of 
neogenin transmembrane and cytoplasmic 
domains in the process of HJV release.     
Recent studies indicate that the HJV cleavage is 
mediated by the proprotein convertase, furin 
(24,25).  Furin is predominantly localized in the 
TGN and cycles between the TGN and the plasma 
membrane (52). Like transmembrane proteins, 
furin is synthesized in the ER, and like other pro-
enzymes, it is activated until it reaches its 
destination which is the TGN in the case of furin 
(52).  This specific localization of furin and its 
trafficking between the plasma membrane and the 
TGN and our data, therefore, do not favor the 
findings in a recent report stating that the furin-
mediated HJV shedding occurs in the ER (25).  On 
the basis of our results, the endocytic 
compartments are most likely the sites of HJV 
shedding.  First, HJV release is coupled to the 
increased neogenin degradation in lysosome.  
Second, HJV undergoes endocytosis, and blockage 
of HJV internalization inhibits HJV release.   
Previous studies indicate that the endocytosis of 
many GPI-anchored proteins is through dynamin-
independent but cholesterol-dependent pathway, 
since GPI-anchored proteins are present at the 
surface in cholesterol-dependent nanoscale 
clusters (45,47-49).  Our results showing that 
cholesterol inhibitor, but not dynamin inhibitor, is 
able to decrease HJV internalization, tend to 
support that the endocytosis of HJV follows this 
pathway.  These observations also imply that HJV 
endocytosis may depend on its GPI-anchor.  
However, this does not exclude other possibilities 
because neogenin seems to play the critical role in 
this process. Neogenin has a cytoplasmic domain 
of 388 amino acids (33).  The role of neogenin 
cytoplasmic domain in this process remains to be 
determined. 
On the basis of our data, we propose a model 
for the neogenin-required and furin-mediated HJV 
shedding.  The association of HJV with neogenin 
on plasma membrane triggers the internalization of 
both proteins as a complex.  The complex is then 
retrieved into a compartment, in which HJV is 
exposed to furin for cleavage and the subsequent 
release whereas neogenin is sorted for degradation 
in lysosome.  The fraction of HJV that is unable to 
associate with neogenin, would be targeted for 
degradation.  
Soluble HJV plays a critical role in the 
inhibition of hepatic hepcidin expression through 
the BMP signaling (22,24,26,27).  Studies in 
transfected cells indicate holo-Tf and/or non-Tf 
iron inhibits the shedding of HJV (20,22,37).  
Animal studies suggest that serum HJV could be 
derived from both skeletal muscle and liver 
hepatocytes (20).  These observations, therefore, 
support that serum HJV plays a critical role in the 
regulation of iron homeostasis.  The findings in 
the present study showing that soluble neogenin 
competitively blocks HJV release and HJV release 
requires HJV endocytosis, imply that the 
regulation of HJV release by holo-Tf might take 
place at the cell surface, after internalization or 
during the retrograde transport.  Thus holo-Tf 
would disrupt HJV-neogenin complex similar to 
soluble neogenin and thereby modulate HJV 
release.  However, the mechanism by which holo-
Tf interferes with HJV release still remains to be 
elucidated. 
In summary, this study demonstrates that 
neogenin is not required for HJV trafficking from 
the ER to the plasma membrane, but the HJV-
neogenin interaction at the cell surface is essential 
for HJV release.  Together with the specific 
localization of furin, the findings that HJV 
endocytosis is required for its release, suggest that 
neogenin-dependent retrograde trafficking of HJV 
to furin positive compartments is necessary for 
HJV shedding.  How this process is regulated by 
iron still remains to be explored and will be the 
subject of future research.   
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FIGURE LEGENDS 
 
Figure 1.  Knockdown of neogenin blocks HJV release, but does not affect HJV cell surface expression.  
We used siRNA specific to human neogenin and Lipofectmine RNAiMax to knockdown the endogenous 
neogenin in control and HJV-HepG2 cells as described in the section of Experimental Procedures.  
Scrambled siRNA was used as a parallel negative control.  A. Cell-associated protein.  PI-PLC digestion 
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was used to examine the effect of neogenin knockdown on the dynamic HJV expression on cell surface.  
Cells from above were incubated in presence or absence of PI-PLC at the concentration of 1 unit/ml for 2 
hr in 37°C CO2 incubator.  HJV, neogenin (neo) and actin in cell lysates (L) and the HJV in supernatant 
(HJV sup) were detected by western blot analysis.  B. HJV release.  At 24 hr after the second transfection 
of cells with siRNA, cells were pooled and sub-cultured into 12-well plates with complete medium 
containing 10% FCS.  About 48 hr later, 100 µl of the conditioned medium (CM) was subjected to SDS-
PAGE and western blot analysis for HJV (HJV CM).  C. Flow cytometry analysis of the cell surface HJV.  
Flow cytometry analysis of cell surface HJV was analyzed as described above in the section of 
experimental procedures and expressed as arbitrary units (a.u.).  The average of four individual analyses 
and the standard deviation were presented.  All other experiments were repeated at least three times with 
consistent results.      
 
Figure 2.  The ectodomain of neogenin blocks HJV release.  HFE2 stably transfected (HJV) and empty 
vector transfected control (C)-HepG2 cells in 12-well plate were incubated in the absence or presence of 
the soluble ectodomain of neogenin at 0-1000 nM for 24 hrs.  Approximate half of the cell lysate (L) and 
20% of the CM was subjected to western blot analysis for HJV and neogenin (neo).  Actin was also 
probed in the lysate as a protein loading control.  Experiments were repeated three times with consistent 
results. 
 
Figure 3.  HJV release is correlated with neogenin degradation.  A. Expression of HJV, but not G320V 
mutant, decreases the level of neogenin protein in HepG2 cells.  Cell lysate from 2 x 105 cells and CM 
from 0.8 x 105 cells of overnight culture were subjected to SDS-PAGE, followed by immunodetection of 
the HJV in both cell lysates (HJV L) and CM (HJV CM), and neogenin (neo L) and actin in the lysate.  B. 
PI-PLC digestions.  HJV, G320V and control-HepG2 cells in 12-well plates at approximate 70% 
confluence were incubated in 300 µl MEM medium with or without addition of PI-PLC (1 unit/ml) for 3 
hr at 37°C CO2 incubator.  Approximately half of the cell lysate or supernatant were subjected to SDS-
PAGE, followed by immunodetection of HJV in both cell lysate (L) and supernatant (sup), and neogenin 
(neo) and actin in the lysate.  C. Bafilomycin A increases cellular neogenin.  Control (C) and HJV-HepG2 
cells in 12-well plate were incubated for 4 hr in complete medium with or without addition of 100 nM 
bafilomycin A (Baf).  Neogenin, HJV and actin in cell lysate (L) and HJV in about one-third of CM were 
detected by western blot using the specific antibodies.  All the experiments were repeated at least three 
times with consistent results. 
 
Figure 4. Depletion of cholesterol inhibits HJV release.  A. Dynasore does not inhibit HJV release.  HJV-
HepG2 cells in 12-well plates were incubated in the presence of 0, 80 and 160 µM of dynasore for 2 hrs at 
37°C.  HJV in both cell lysate (L) and 50% of CM was detected by western blot.  B. 125I-Tf-uptake.  
HepG2 cells in 6-well plates with approximate 80% confluence were first pre-incubated in absence or 
presence of dynasore (80 and 160 µM) (D80, D160) and filipin (10 µg/ml) (F) for 30 min at 37°C.  125I-Tf 
uptake was initiated by incubating the cells in the presence of 50 nM 125I-Tf and the same concentrations 
of inhibitors.  After an 8 min of incubation at 37°C, membrane-bound 125I-Tf was removed by acid wash.  
The 125I radioactivity was counted.  The inclusion of 1 mg/ml unlabeled cold Tf was used as the non-
specific uptake control.  The rates of specific uptake in presence of inhibitors were expressed as the 
percentage of the corresponding controls.  Results are from four individual experiments.  * P = 0.0281; ** 
P <0.0001.  C. Wild type and K44A mutant dynamin.  HJV-HepG2 cells in 12-well plates were infected 
with the mixture of tTA-activator virus and different amounts of adenovirus containing either wild type or 
K44A mutant dynamin (0, 0.048, 0.096, 0.19 and 0.38 µl stock virus/well).  tTA-activator virus alone was 
used as a negative control.  The cells were first incubated for about 18 hr to allow the expression of 
introduced dynamin.  Afterwards, about 20% of the CM collected from the incubation between 18 and 42 
hr post-infection was detected for HJV by western blot.  In addition, dynamin (dyn), HJV and actin in the 
cell lysate (L) at 42 hr post-infection were also analyzed. D. Filipin inhibits HJV release.  HJV-HepG2 
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cells in 12-well plates were incubated in the presence of 0, 1, 5 and 10 µg/ml of filipin for 2 hrs at 37°C.  
HJV in both cell lysate (L) and 50% of CM was detected by western blot.  E. Filipin inhibits the 
biotinylated cell surface HJV release.  Cell surface proteins in HJV-HepG2 cells were biotinylated at 4°C, 
followed by incubation in the presence of 0, 10 and 20 µg/ml of filipin at 37°C for 2 hrs.  The biotinylated 
HJV that was released into the medium (CM) (HJV CM), as well as the total biotinylated cell surface 
HJV (T) (HJV S), was isolated using streptavidin agarose beads and subjected to western blot (lower 
panel).  The total HJV in cell lysate (L) was also detected (upper panel).  All the experiments were 
repeated at least three times with consistent results.  In each experiment, the lysate and CM from control-
HepG2 cells (C) were included as a negative control for HJV. 
 
Figure 5.  HJV undergoes endocytosis.  A. Internalization of biotinylated cell surface HJV.  Cell surface 
proteins in control (C) and HJV-HepG2 cells were biotinylated at 4°C, followed by incubation at 37°C for 
0 and 10 min (0’ and 10’).  After stripping the biotin remaining on cell surface, the internalized HJV 
(intrnlzd) was isolated using streptavidin agarose beads and subjected for western blot.  About 10% of 
lysate from the cells without biotinylation (lysate) and the total biotinylated cell surface HJV without 
incubation and stripping (cs) were included for the analysis.  B. Filipin inhibits HJV internalization.  The 
experiments were conducted essentially the same as described in A, except that the biotinylated cells were 
first pre-incubated in the absence or presence of 10 µg/ml filipin or 160 µM dynasore  (dynas) at 4°C for 
30 min before the incubation at 37°C.  
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Figure 1.  Zhang et al.
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Figure 2.  Zhang et al.
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Figure 3.  Zhang et al.
A.       C        HJV    G320V
neo (L)
actin (L)
HJV (CM)
HJV (L)
B.          C         HJV     G320V
       -     +    -     +      -     +
neo (L)
HJV (L)
PI-PLC
HJV (sup)
C.
Baf    -       +        -        +
  C              HJV
neo (L)-
HJV (L)-
actin (L)-
HJV (CM)-
-206 kD
-45 kD
-45 kD
-206 kD
-45 kD
-45 kD
-45 kD
-45 kD
-31 kD
-31 kD
 at CALIFO
RNIA INSTITUTE O
F TECHNO
LO
G
Y on April 29, 2008 
w
w
w
.jbc.org
D
ow
nloaded from
 
Figure 4. Zhang et al.
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Figure 5. Zhang et al.
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